November 13th 2018
Roy S. Herbst, MD, PhD, discusses where future research is headed for immunotherapy in lung cancer.
November 11th 2018
D. Ross Camidge, MD, PhD, discusses the crowded landscape of oncogene-driven non–small cell lung cancer.
November 10th 2018
Peter E. Clark, MD, discusses the role of surgery in the rapidly evolving treatment paradigm for patients with renal cell carcinoma.
November 9th 2018
Balazs Halmos, MD, MS, discusses overcoming acquired resistance and other next steps needed to advance the oncogene-driven non–small cell lung cancer paradigm.
November 2nd 2018
Claud M. Grigg, Jr, MD, discusses the evolving treatment options in the frontline setting for patients with renal cell carcinoma.
Ronald de Wit, MD, PhD, discusses the clinical implications of pembrolizumab in the non–muscle invasive bladder cancer patient population.
November 1st 2018
Asim Amin, MD, discusses the current role of checkpoint inhibitors in advanced renal cell carcinoma and where the future is heading in this space.
October 31st 2018
Earle Burgess, MD, discusses the shifting paradigm of metastatic castration-sensitive prostate cancer.
Kashyap Patel, MD, discusses biosimilars and other potential cost-controlling measures in cancer care.
October 30th 2018
Missak Haigentz, MD, discusses the impact of EGFR TKIs on the treatment of patients with non–small cell lung cancer.
October 29th 2018
Neil P. Shah, MD, PhD, discusses emerging agents and the tyrosine kinase inhibitor discontinuation approach in the landscape of chronic myeloid leukemia.
Michelle E. Melisko, MD, discusses the clinical implications of the TAILORx and MINDACT studies.
Maurie Markman, MD, reflects on practice-changing advances during his career and discussed the future of gynecologic cancer treatment.
Lawrence D. Kaplan, MD, discusses recent updates and next steps in the expanding paradigm of Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma.
October 28th 2018
Neil Morganstein, MD, discusses the intriguing PACIFIC results and the future role of immunotherapy in non–small cell lung cancer.
October 25th 2018
Brian T. Hill, MD, PhD, discusses recent advances and regulatory decisions in the treatment of patients with chronic lymphocytic leukemia.
Hossein Borghaei, DO, MS, discusses immunotherapy selection for the treatment of patients with non–small cell lung cancer.
October 23rd 2018
Josep M. Llovet, MD, PhD, discusses the rapidly evolving treatment landscape for hepatocellular carcinoma and the work that lies ahead.
Ramsey N. Asmar, MD, discusses recent advances and next steps in small cell lung cancer.
Deborah A. Bradley, MD, discusses how recent clinical trials have impacted patients with nonmetastatic castration-resistant prostate cancer and what the future holds for them.